Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma

Author(s): Roula A. Farah, Soumana C. Nasser, Racha A. Sabbagh, Pele B. Dina and Toufic A. Eid

Volume 6, Issue 2, 2011

Page: [97 - 99] Pages: 3

DOI: 10.2174/157488511795304912

Price: $65

Abstract

Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patients quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.

Keywords: ET-743, pediatric solid tumors, refractory sarcoma, Trabectedin, neutropenia, diagnosis, chemotherapeutic agents, palliative tumor, osteosarcoma, dose limiting toxicity

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy